Suppr超能文献

慢性鼻-鼻窦炎药物治疗随机对照试验中的安慰剂效应:一项系统评价与荟萃分析

The placebo effect in randomized-controlled trials of medical treatments for chronic rhinosinusitis: A systematic review and meta-analysis.

作者信息

Pipaliya Royal M, Duckett Kelsey A, Monaghan Neil P, Miller Emma Marin, Young Gabrielle, Brennan Emily A, Nguyen Shaun A, Soler Zachary M, Schlosser Rodney J

机构信息

Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.

MUSC Libraries, Medical University of South Carolina, Charleston, South Carolina, USA.

出版信息

Int Forum Allergy Rhinol. 2024 Mar;14(3):695-710. doi: 10.1002/alr.23302. Epub 2023 Nov 20.

Abstract

BACKGROUND

The placebo effect observed in clinical trials evaluating medical treatments for chronic rhinosinusitis (CRS) is not well understood. This systematic review and meta-analysis sought to characterize the placebo effect present within CRS outcomes.

METHODS

A systematic review of PubMed, Scopus, and Cumulated Index in Nursing and Allied Health Nursing (CINAHL) was performed. Randomized controlled trials (RCTs) evaluating medical treatments for CRS versus placebo were included. We assessed patient-reported (sino-nasal outcome test 22 [SNOT-22], nasal obstruction, sense of smell, nasal obstruction visual analogue score [VAS], sense of smell VAS, anterior rhinorrhea, and postnasal drip) and objective (Lund-Mackay Computed tomography (CT) score, peak nasal inspiratory flow [PNIF], nasal polyp scores, 40-item Smell Identification Test, serum IgE, and blood eosinophil levels) outcomes.

RESULTS

Twenty-one RCTs were included, comprising 1437 patients (mean age 49.2 years). Biologics were the most common treatment investigated (n = 9). Eleven studies administered background steroids along with placebo. Following placebo administration, multiple patient-reported outcomes significantly decreased, including SNOT-22 (mean difference -9.49, 95% confidence interval [CI] [-11.26, -7.73]), nasal obstruction (-0.33 [-0.54, -0.13]), sense of smell (-0.22 [-0.33, -0.11]), nasal obstruction VAS (-2.47 [-2.87, -2.06]), and loss of smell VAS (-2.31 [-4.14, -0.47]) scores. For objective measures, significant changes occurred in Lund-Mackay CT score (-0.82, [-1.48, -0.16]) and PNIF (4.70, [4.76, 24.64]) with placebo. Placebo arms had the greatest impact when no background medications were used.

CONCLUSIONS

Placebo treatments have a statistically and potentially clinically significant effect on patient-reported and some objective CRS outcomes. Further investigation is required to fully understand placebo effect, which could improve assessment of RCTs and impact patient care.

摘要

背景

在评估慢性鼻-鼻窦炎(CRS)医学治疗方法的临床试验中观察到的安慰剂效应尚未得到充分理解。本系统评价和荟萃分析旨在描述CRS结局中存在的安慰剂效应。

方法

对PubMed、Scopus和护理及相关健康护理累积索引(CINAHL)进行系统评价。纳入评估CRS医学治疗与安慰剂对照的随机对照试验(RCT)。我们评估了患者报告的结局(鼻-鼻窦结局测试22[SNOT-22]、鼻塞、嗅觉、鼻塞视觉模拟评分[VAS]、嗅觉VAS、前鼻漏和后鼻滴漏)和客观结局(Lund-Mackay计算机断层扫描[CT]评分、鼻吸气峰流速[PNIF]、鼻息肉评分、40项嗅觉识别测试、血清IgE和血液嗜酸性粒细胞水平)。

结果

纳入21项RCT,共1437例患者(平均年龄49.2岁)。生物制剂是研究最常见的治疗方法(n = 9)。11项研究在给予安慰剂的同时给予背景类固醇。给予安慰剂后,多项患者报告的结局显著改善,包括SNOT-22(平均差值-9.49,95%置信区间[CI][-11.26,-7.73])、鼻塞(-0.33[-0.54,-0.13])、嗅觉(-0.22[-0.33,-0.11])、鼻塞VAS(-2.47[-2.87,-2.06])和嗅觉丧失VAS(-2.31[-4.14,-0.47])评分。对于客观指标,安慰剂组的Lund-Mackay CT评分(-0.82,[-1.48,-0.16])和PNIF(4.70,[4.76,24.64])发生显著变化。在未使用背景药物时,安慰剂组的影响最大。

结论

安慰剂治疗对患者报告的以及一些客观的CRS结局具有统计学意义且可能具有临床意义。需要进一步研究以充分理解安慰剂效应,这可能会改善RCT的评估并影响患者护理。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验